DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Rhea-AI Summary

DICE Therapeutics, a biopharmaceutical company traded on Nasdaq under the symbol DICE, announced its participation in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, scheduled for March 30, 2023, at 4:00 p.m. ET. The event will focus on DICE's novel oral therapeutic candidates targeting chronic diseases in immunology, utilizing its proprietary DELSCAPE technology platform. A live and archived webcast will be available for 90 days post-event on the company's website. DICE is dedicated to developing effective oral treatments against key immunology targets like IL-17 and integrin α4ß7, aiming to match systemic biologics' potency.

SOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today announced management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 4:00 p.m. ET.

A live and archived webcast of the fireside chat will be accessible under “News & Events” in the Investors section of the company's website for 90 days after the event.

About DICE Therapeutics, Inc.
DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting the integrin α4ß7 for the treatment of inflammatory bowel disease.

Contacts:

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
investors@dicetx.com

 

FAQ

When will DICE Therapeutics participate in the H.C. Wainwright conference?

DICE Therapeutics will participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023, at 4:00 p.m. ET.

How can I access the DICE Therapeutics fireside chat?

The fireside chat will be accessible via a live and archived webcast under the 'News & Events' section in the Investors part of DICE Therapeutics' website for 90 days after the event.

What is the focus of DICE Therapeutics' presentation at the conference?

DICE Therapeutics will present its pipeline of novel oral therapeutic candidates aimed at treating chronic diseases in immunology using its DELSCAPE technology.

What therapeutic targets is DICE Therapeutics developing treatments for?

DICE Therapeutics is developing oral therapeutics targeting the pro-inflammatory molecule IL-17 and integrin α4ß7 for conditions like inflammatory bowel disease.